The identified risk gene signature of locally advanced HNSCC and the potential therapeutic drug trichostatin A for the RR and PD-L1-high group are worth being further studied in a prospective homogenous cohort. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.